Clene: CNM-Au8® Preserved ALS Patient Function, Slowed Disease Progression in Phase 2

 

• Significant preservation of function (ALSFRS-R) from randomization to 48 weeks (p=0.0159)
• Significant preservation of function (ALSFRS-R) during the long-term open-label extension (OLE) week 24 to 120 weeks from randomization (p=0.0057)
• Significantly reduced risk of ALS clinical worsening by 52% over 120 weeks (HR: 0.478, p=0.0494)
• CNM-Au8 treatment was well-tolerated without long term safety concerns

https://www.biospace.com/article/releases/new-data-show-cnm-au8-preserved-als-patient-function-and-slowed-disease-progression-in-the-open-label-extension-of-the-phase-2-rescue-als-trial/